This is a past event. Registration is closed. View other Viva Biotech Holdings events.
Yuqiao Shen
CEO of AceLink Therapeutics,Inc.Yuqiao (Jerry) Shen, Ph.D.
Chief Executive Officer; Co-founder
Dr. Shen brings more than 20 years of pharmaceutical experience with a focus on drug development for cancer, genetic diseases and rare diseases. Before founding AceLink in 2019, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development. He joined BioMarin in 2010 when the company acquired LEAD Therapeutics, a small drug discovery company where he served as VP of Drug Discovery Biology. Prior to LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded. Prior to that, he worked at Onyx Pharmaceuticals, where he served at positions with increasing responsibilities and helped development of oncolytic viruses and gene delivery viral vectors.
Dr. Shen holds B.S. in Physiology from Fudan University, PhD in Molecular Biology from State University of New York at Buffalo, and received post-doctoral training in Dr. Thomas Shenk’s lab at Princeton University. He has co-authored more than 35 peer-reviewed papers and is a co-inventor in more than 30 issued and pending patents. In 2018, Talazoparib, a cancer drug for which he spent many years of his career both at LEAD and at BioMarin, received marketing approval from FDA.
Shunqi Yan
COO & Founder of Arthrosi Therapeutics, Inc.Ph.D., Rutgers University
Experience in Schrodinger, Arquele, Valeant, IGNYTA
Key participant in 7 clinical drugs, including 2 first-in-class drugs
Arthur Suckow
Founder of DTxExperience in Johnson & Johnson, AstraZeneca and Regulus Therapeutics; Extensive experience in fatty acid pharmacology; Numerous awards including a Beckman Fellowship, NSF graduate research fellowship.
Hua Lin
Co-founder of ForkheadbioCo-founder, Chief Scientific Officer
Dr. Lin completed her PhD at the University of Michigan. is a postdoctoral and assistant research scientist at columbia university, after which she continues to be a senior research biologist at merck and head/chief research scientist at elili.
Zhanpeng Jiang
CEO of Shanghai Epican Genetech Co,Ltd纽约大学斯顿商学院MBA，哈佛大学商学院高管领导力培训项目，特许金融分析师（CFA）。从事金融、投资与商业管理26年，曾管理百亿美金股权投资基金，并获得两项Lipper 亚太区最佳基金大奖对冲基金与PE基金公司秦岭资本联合创始人，曾参与投资多项早中期生物、医疗项目，拥有丰富的董事会工作经验。美国Elixell Therapeutics Inc 干细胞治疗公司联合创始人、董事长，多间美国生物技术公司董事。
Yimin Zou
Founder of VersaPeutics, Inc.Postdoctoral Fellowship at University of California, San Francisco and San Diego
Ph.D. University of California, Davis and San Diego
~45 publications
Zengquan Wang
Founder of Technoderma王增全博士系国际知名的皮肤病药物研发专家，从事皮肤项目研究和药物研发20多年。王博士1991年获得美国华盛顿州立大学博士学位，并随后于美国华盛顿州立大学、美国密西根大学开展博士后研究。1996年起一直从事皮肤病相关药物的研发，先后任职于OSI药物研发公司、辉瑞制药皮肤药部门（担任研发总监/副研究员一职）、免疫药部门以及阿斯利康等知名药企，曾在《新英格兰医学》，《自然》，《自然医学》等世界著名科学杂志上发表署名文章20多篇。
James Sietstra
Founder of TotientPresident of Seven Bridges Genomics from 2012-2018; led commercial launches, formed 15+ pharma partnerships, raised $120M+ in equity capital, and invested in complementary technologies; Serial entrepreneur, successfully exited last three businesses, which generated $900M in total revenue since founding.
David Xu
CBO at Viva BiotechPh.D. from University of California, Los Angeles
Postdoctoral research at the Scripps Research Institute
M.B.A from Wharton School of Business, University of Pennsylvania
Worked in Purdue, Sandoz, and Novartis